CEO of the SFDA Discusses Ways to Enhance Drug Quality and Safety with International Counterparts During the ICMRA Summit in Amsterdam

The CEO of the Saudi Food and Drug Authority (SFDA), H.E. Dr. Hisham S. Aljadhey, held several meetings with international counterparts on the sidelines of his participation in the International Coalition of Medicines Regulatory Authorities (ICMRA) Summit 2025, held in Amsterdam from October 21 to 23.

The meetings included a meeting with Dr. Leandro Safatle, the Director-President of the Brazilian Health Regulatory Agency (ANVISA) and two bilateral meetings: one with Dr. Ali El-Ghamrawy, Chairman of the Egyptian Drug Authority (EDA), and another with Mr. Lawrence Tallon, Chief Executive of the British Medicines and Healthcare Products Regulatory Authority (MHRA).

The discussions focused on strengthening cooperation and communication between regulatory authorities to achieve common goals and enhance the safety, quality, and efficacy of medicines and vaccines. They also reviewed leading practices and policies regarding artificial intelligence to promote innovation and growth in the pharmaceutical sector, in addition to several other topics of mutual interest.

ICMRA serves as an international platform for enhancing collaboration among regulatory bodies, addressing drug safety challenges with innovative mechanisms, and developing related regulations and systems. This aligns with the objectives of the health sector transformation program within the Kingdom's Vision 2030.